The Belgian company recently received €3.6 million to develop the signature into a clinical test within the next three years.
The company presented its findings last week at the 2016 Gastrointestinal Cancer Symposium and is preparing to launch the assay in the US later this year.
The agreement covers GynTect, which uses epigenetic biomarkers and methylation-specific PCR to determine if an HPV-positive patient is at risk for developing cervical cancer.
Oncgnostics will use MDxHealth's methylation-specific PCR in the GynTect test for cervical cancer, the fourth such test to use the technology.
Asuragen said that that in the second half of this year it will release research-use-only reagents for evaluating FMR1 methylation status in the hopes of obtaining independent validation of the technology.
Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.
Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.
Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.
In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.